Corcept Therapeutics Incorporated (CORT)
Cash conversion cycle
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 416.32 | 435.34 | 1,154.38 | 1,240.63 | 1,383.43 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
| Cash conversion cycle | days | 416.32 | 435.34 | 1,154.38 | 1,240.63 | 1,383.43 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 416.32 + — – —
= 416.32
The cash conversion cycle of Corcept Therapeutics Incorporated has shown a decreasing trend over the past five years, indicating efficiency in managing its working capital. On December 31, 2020, the cash conversion cycle was 1,383.43 days, which gradually decreased to 416.32 days by December 31, 2024. This signifies that the company is taking less time to convert its investments in inventory and accounts receivable into cash.
A lower cash conversion cycle suggests that Corcept Therapeutics is improving its liquidity position and operating efficiency. The company seems to be effectively managing its inventory and collecting receivables, which may lead to better cash flow management and overall financial health. The significant reduction in the cash conversion cycle from 2020 to 2024 reflects the company's ability to streamline its operations and optimize its working capital utilization.
Peer comparison
Dec 31, 2024